Figure 2.

Detection of DLL3 expression at the surface of cells using an anti-DLL3 scFv

(A) Schematic representation of the His-tagged scFv targeting DLL3 (aDLL3scFv) and the detection of cells expressing DLL3 using this molecule.

(B) Representative flow cytometry analysis of DLL3 expression in 293T cells expressing exogenous mouse DLL3 using aDLL3scFv (from n = 3 biological replicates).

(C) Quantification of DLL3 detection in 293T-DLL3 cells from (B) and human SCLC cell lines.

(D) Schematic representation of AF680-labeled aDLL3scFv (aDLL3AF680).

(E) Representative flow cytometry showing binding activity of aDLL3AF680 (from n = 3 biological replicates).

(F) Quantification of (E) in human SCLC cell lines.

(G) Whole body fluorescent images of H82 tumor xenografts with 2 nmol of AF680-labeled scFv injected via the tail vein (left). Tumors (T) and kidneys (K) are indicated. Quantification of imaging signals (right), reported as the total flux (p/s) (n = 3).

(H) Representative ex vivo imaging of two H82-bearing mice in (G).

Unpaired t-test, data represented as mean ± s.d. ∗p<0.05, ∗∗p<0.01, ∗∗∗p<0.001. See also Figure S2.